This article is more than 5 years old. Information may no longer be current.

Nitric-oxide-donating technology shows good preclinical results for IOP lowering

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SOPHIA ANTIPOLIS, France — Preclinical studies showed a nitric-oxide-donating technology to be "significantly more effective" than a reference drug for treating a model of elevated IOP, according to NicOx, the company developing the compound.

NicOx also announced that it has signed an exclusive agreement with Pfizer, granting Pfizer worldwide rights to the proprietary nitric-oxide-donating technology in the field of ophthalmology.

The company described three preclinical studies of the compound in a press release. In one in vivo model, IOP was elevated transiently, followed by treatment with the NicOx compound or a reference drug. The mean IOP peak occurred between 60 and 90 minutes, and the NicOx compound demonstrated a significantly lower IOP profile than the reference drug, the press release said.

In a second in vivo disease model, the compound achieved a maximum mean decrease in IOP of 12.8 mm Hg at 4 hours after administration and was superior to the reference drug, the company said. A third in vivo model showed that the compound achieved a maximum mean decrease of 9.2 mm Hg 2 hours after the first dose, the release said.

In the deal with Pfizer, according to the press release, Pfizer will pay NicOx $27.3 million during the first year, and NicOx my receive total potential milestones in excess of $356.2 million.